Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.
ADVERTISEMENT
ADVERTISEMENT
2026 Copyright © News-Matic.com. All Rights Reserved
